Evoke Pharma Price to Sales Ratio 2012-2024 | EVOK

Historical PS ratio values for Evoke Pharma (EVOK) over the last 10 years. The current P/S ratio for Evoke Pharma as of January 23, 2025 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Evoke Pharma P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2025-01-23 4.53 0.38
2024-09-30 4.76 $12.08 0.39
2024-06-30 6.35 $15.78 0.40
2024-03-31 7.32 $17.97 0.41
2023-12-31 12.60 $18.58 0.68
2023-09-30 16.56 $15.61 1.06
2023-06-30 19.80 $12.99 1.52
2023-03-31 22.80 $10.69 2.13
2022-12-31 32.16 $9.62 3.34
2022-09-30 22.44 $8.20 2.74
2022-06-30 38.88 $9.33 4.17
2022-03-31 71.28 $8.62 8.26
2021-12-31 79.20 $7.20 10.99
2021-09-30 187.20 $5.59 33.49
2021-06-30 197.28 $1.47 134.15
2021-03-31 263.52 $0.42 630.23
2020-12-31 371.52 0 0.00
2020-09-30 675.36 0 0.00
2020-06-30 509.76 0 0.00
2020-03-31 167.04 0 0.00
2019-12-31 233.28 0 0.00
2019-09-30 123.84 0 0.00
2019-06-30 90.00 0 0.00
2019-03-31 216.00 0 0.00
2018-12-31 357.12 0 0.00
2018-09-30 429.12 0 0.00
2018-06-30 360.00 0 0.00
2018-03-31 299.52 0 0.00
2017-12-31 325.44 0 0.00
2017-09-30 480.96 0 0.00
2017-06-30 368.44 0 0.00
2017-03-31 446.40 0 0.00
2016-12-31 290.88 0 0.00
2016-09-30 325.44 0 0.00
2016-06-30 986.40 0 0.00
2016-03-31 732.96 0 0.00
2015-12-31 475.20 0 0.00
2015-09-30 419.04 0 0.00
2015-06-30 753.12 0 0.00
2015-03-31 1015.20 0 0.00
2014-12-31 849.60 0 0.00
2014-09-30 791.93 0 0.00
2014-06-30 1164.96 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.006B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $24.935B 8.18
Dr Reddy's Laboratories (RDY) India $12.596B 24.10
BridgeBio Pharma (BBIO) United States $6.773B 0.00
Bausch Health Cos (BHC) Canada $2.792B 2.06
Supernus Pharmaceuticals (SUPN) United States $2.108B 28.70
Amphastar Pharmaceuticals (AMPH) United States $1.738B 10.44
Personalis (PSNL) United States $0.396B 0.00
Taysha Gene Therapies (TSHA) United States $0.314B 21.86
Assembly Biosciences (ASMB) United States $0.095B 0.00
Sol-Gel Technologies (SLGL) Israel $0.025B 0.00
Teligent (TLGT) United States $0.000B 0.00